R&D How Japan is pioneering the future of oncology clinical tria... Discover how Japan is leading the way in oncology clinical trials through the implementation of decentralised clinical trials
News Shionogi gets approval in Japan for ADHD digital therapeutic Shionogi will market the EndeavorRide app, originally licensed from Akili, in Japan following its approval by the MHLW regulator.
News First global approval for Daiichi Sankyo's Dato-DXd Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.
News Eisai debuts biliary tract cancer drug in Japan Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
News Lilly gets second approval, in Japan, for Alzheimer's drug Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.
News Investors take issue with Taisho Pharma’s buyout price Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court, after failing to reach an agreement on the price.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.